Cipla Ltd — Q4 FY25
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), Nort...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
71%Questions answered0Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Market positioning for Nano Paclitaxel launch in U.S.
Asked by Kunal Dhamesha, Macquarie
Management gave market structure but did not quantify expected market share or specific advantages.
no market share estimatevague on positioning
Read the exchange
Question
how are we looking at this market given there are other players with a 505(b)(2) kind of product? With our product, how are we positioned to gain market share?
Umang Vohra, Managing Director and Global CEO
Bulk of the market is, I think there are what we know, there is one NDA player, and there are two generics. I think one of the generics is any. We will continue to expand for ANDA generics because they are substitutable.
Partial answer
High priority
Total addressable market for Nano Paclitaxel
Asked by Kunal Dhamesha, Macquarie
Provided historical gross market size but did not give current net market estimate.
no current net market size given
Read the exchange
Question
What would be your estimate of the total addressable market now?
Umang Vohra, Managing Director and Global CEO
the market was $800 million-$900 million pre-generic. I think the IMS would still show it at that level, but there would be a gross to net to bring the market down
Answered
High priority
Advair launch timeline and regulatory status
Asked by Kunal Dhamesha, Macquarie
Provided clear timeline (FY2026) and explained dependency on FDA priority.
Read the exchange
Question
I think I missed any commentary on Advair and overall on the respiratory pipeline that we suggested. Could you please?
Umang Vohra, Managing Director and Global CEO
Advair, as we mentioned, will be commercialized from our site in the U.S. ... we definitely see it as an FY 2026 launch. The question is, depending on the priority of the filing, we will probably either be launching it in the early part of the year or the later part of the year.
Partial answer
Medium priority
Impact of potential U.S. pharma tariffs
Asked by Kunal Dhamesha, Macquarie
Acknowledged no impact but gave no concrete data or partner feedback.
no specific detailsevolving situation
Read the exchange
Question
Is there any update on your side in the U.S. market? If you are getting something from your partners or distributors, any color would be helpful there.
Ashish Adukia, Global CFO
We have not in any way got impacted by any. This is an evolving situation. ... the most recent announcement does not really impact the generic players. In fact, it may just benefit.
Partial answer
High priority
Lanreotide supply normalization timeline
Asked by Damayanti Kerai, HSBC
Indicated improvement but did not commit to a quarter for full normalization.
no specific timeline for full recovery
Read the exchange
Question
for Lanreotide, how should we look at the normality or, yeah, normality coming back in the supplies for the U.S. market?
Umang Vohra, Managing Director and Global CEO
quarter four was significantly higher than quarter three. And in terms of volume, and also this quarter, we are coming back to normalcy. ... the product is quite significantly back into the channel.
Answered
Medium priority
R&D spending outlook and focus areas
Asked by Damayanti Kerai, HSBC
Provided clear R&D spend cap and listed focus areas.
Read the exchange
Question
In terms of spending the 2026, 2027, how should we look at the R&D cost? Which are the focus segments in near term?
Umang Vohra, Managing Director and Global CEO
we are really guiding to not being ever higher than 6%-6.5%, right? That is for a full year basis. ... Focus areas will continue to be respiratory, will continue to be injectables, will continue to be products in the products which are for India, including the GLP-1s
Answered
High priority
Reason for lower margin guidance and Revlimid impact
Asked by Surya Narayan Patra, PhillipCapital India Pvt Ltd
Clearly attributed margin guidance to Revlimid exclusivity loss.
Read the exchange
Question
It looks like slightly lower than last year number. Is it because the Revlimid number is likely to be lower, or is it because Revlimid is started seeing any kind of price correction?
Umang Vohra, Managing Director and Global CEO
generic Revlimid, which will go out of exclusivity towards the last quarter. That will certainly have an impact on overall margin. That's why we are guiding towards the margin number that we've given.
Partial answer
Medium priority
CapEx for FY2026 and GLP-1 preparedness
Asked by Surya Narayan Patra, PhillipCapital India Pvt Ltd
Gave CapEx as % of revenue but no absolute number; GLP-1 readiness not quantified.
no specific CapEx numbervague on GLP-1 readiness
Read the exchange
Question
what is our thought process there? For the peptide as well as the GLP opportunity, how prepared are we?
Umang Vohra, Managing Director and Global CEO
About 4% roughly or 5% of your revenue, yeah, somewhere around that would be the figure for the CapEx, 5% of revenue you could take.
Partial answer
High priority
India market growth outlook and Cipla's performance
Asked by Neha Manpuria, Bank of America
Provided industry growth range but did not quantify Cipla's expected outperformance.
no specific Cipla growth number
Read the exchange
Question
how should I think about growth? While we have mentioned higher than IPM growth, what's your overall sense on what the market growth can be there for what the trade generic and branded generic growth for Cipla could be?
Umang Vohra, Managing Director and Global CEO
The overall market growth rate range of 10%-12% has now moved to 8%-10%. ... Cipla will do better than that overall in India.
Answered
Medium priority
Timeline for partnered inhalation asset commercialization
Asked by Shashank Krishnakumar, Emkay Global
Confirmed on track and specified facilities.
Read the exchange
Question
just wanted to check if we are on track to commercialize this asset sometime next year. Also just wanted to check which facility is this asset now filed for.
Umang Vohra, Managing Director and Global CEO
The asset is on track for commercialization. The asset was originally filed from Goa. It will be commercialized from Goa. We are also creating a new filing for, we are also supplementing the file if needed by also having the option of doing this from our U.S. facility.
Partial answer
High priority
Cipliqord launch timeline and Semaglutide update
Asked by Beno Parthi Parmar, Lara Capital
Confirmed Cipliqord FY2027 but declined Semaglutide launch details.
declined Semaglutide detailsvague on Cipliqord
Read the exchange
Question
are we still expecting to launch Cipliqord in FY 2027? ... There is this product, Semaglutide, in which you and your partner have filed for a declaratory judgment. Could you give some details about when do you expect to launch this?
Umang Vohra, Managing Director and Global CEO
27, yes. We should be hopefully there. ... I would rather not provide since the product is competitive.
Answered
High priority
U.S. run rate recovery with Lanreotide and Revlimid
Asked by Beno Parthi Parmar, Lara Capital
Provided specific Q1 U.S. revenue guidance of ~$220M and explained dependency on Revlimid.
Read the exchange
Question
with Lanreotide coming back, are we looking back to getting to our peak U.S. run rate of $250 million a quarter starting next quarter or something like that?
Umang Vohra, Managing Director and Global CEO
If Lenalidomide might stay at where it was now, yes, we would have got there and crossed it. ... we are looking at something like $220 million for the U.S. going forward in the next quarter or so.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| U.S. Q1 FY26 revenue ~$220 million | 220 | 6,730 | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.